Trial · NCT01822496
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival | EGFR: Erlotinib | 21.1 | 95% Confidence Interval 8.5 to NA | months | |
| Progression-free Survival | EGFR: No Erlotinib | 9.2 | 95% Confidence Interval 8.7 to NA | months | |
| Progression-free Survival | ALK: Crizotinib | 14.7 | 95% Confidence Interval 6.4 to 19.5 | months | |
| Progression-free Survival | ALK: No Crizotinib | NA | 95% Confidence Interval NA to NA | months | |
| Percentage of Patients With Complete or Partial Response | EGFR: Erlotinib | 50.0 | 95% Confidence Interval 19.0 to 81.0 | percentage of participants | |
| Percentage of Patients With Complete or Partial Response | EGFR: No Erlotinib | 26.7 | 95% Confidence Interval 4.3 to 49.1 | percentage of participants | |
| Percentage of Patients With Complete or Partial Response | ALK: Crizotinib | 66.7 | 95% Confidence Interval 29.0 to 100.0 | percentage of participants | |
| Percentage of Patients With Complete or Partial Response | ALK: No Crizotinib | 75.0 | 95% Confidence Interval 32.6 to 100.0 | percentage of participants | |
| Number of Patients With Grade 3-5 Adverse Events | EGFR: Erlotinib | 0 | Participants | ||
| Number of Patients With Grade 3-5 Adverse Events | EGFR: No Erlotinib | 0 | Participants | ||
| Number of Patients With Grade 3-5 Adverse Events | ALK: Crizotinib | 0 | Participants | ||
| Number of Patients With Grade 3-5 Adverse Events | ALK: No Crizotinib | 0 | Participants | ||
| Overall Survival | EGFR: Erlotinib | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival | EGFR: No Erlotinib | 35.9 | 95% Confidence Interval 35.9 to NA | Months | |
| Overall Survival | ALK: Crizotinib | NA | 95% Confidence Interval NA to NA | Months | |
| Overall Survival | ALK: No Crizotinib | NA | 95% Confidence Interval NA to NA | Months | |
| Local-regional Progression-free Survival | EGFR: Erlotinib | 25.7 | 95% Confidence Interval 8.5 to NA | Months | |
| Local-regional Progression-free Survival | EGFR: No Erlotinib | NA | 95% Confidence Interval NA to NA | Months | |
| Local-regional Progression-free Survival | ALK: Crizotinib | 14.7 | 95% Confidence Interval 6.4 to 19.5 | Months | |
| Local-regional Progression-free Survival | ALK: No Crizotinib | NA | 95% Confidence Interval NA to NA | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01822496/results